Biotech

All Articles

Regeneron's Opdualag opponent shows 57% feedback cost

.Regeneron is actually back with long-lasting follow-up for its own LAG-3 inhibitor and also PD-1 in...

AstraZeneca posts information on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early check out the performance of its internal antibody-drug co...

iTeos- GSK's TIGIT star reveals relevant remodeling

.After announcing a stage 3 launch based upon good midstage results, iTeos and GSK are actually even...

More collective FDA can easily speed up unusual ailment R&ampD: document

.The FDA should be actually much more available and also collaborative to unleash a surge in commend...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It's an abnormally occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicar...

Atea's COVID antiviral falls short to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has stopped working one more COVID-19 test, however the biotech sti...

Neurocrine's bid to save mental illness possibility falls short

.Neurocrine Biosciences' schizophrenia course pivot has stopped working. The biotech was unable to i...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has actually brought in an overdue access to the radioligand celebration, spending 100 thous...

F 2G rears $100M for 2nd effort to receive brand new antifungal to market

.After F2G's first attempt to acquire a brand-new class of antifungal to market was actually thwarte...

Moderna targets $1.1 B in R&ampD investing cuts, falls 5 systems among success stress

.Moderna has actually vowed to reduce R&ampD costs through $1.1 billion by 2027. The choice to shrin...